CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 186 enrolled
Drug / intervention
Pasireotide +1 moredrug
Likely dose
Pasireotide 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00690430
NCT00690430Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-related Symptoms Are Inadequately Controlled by Somatostatin Analogues.

Novartis Pharmaceuticals·interventional·Posted Jun 4, 2008·Updated Jul 30, 2013

In Brief

A Phase 3 clinical trial evaluating Pasireotide and Octreotide for Symptomatic Refractory Resistant Carcinoid Disease. Completed, enrolled 186 participants across 62 sites in 16 countries.

Detailed Summary

The purpose of this randomized, multicenter, Phase III study was to compare the efficacy of paseriotide LAR and octreotide LAR in patients whose disease-related symptoms are inadequately controlled by currently available somatostatin analogues.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSymptomatic Refractory Resistant Carcinoid Disease
CountriesArgentina, Austria, Belgium, Brazil, Canada, France, Germany, Israel, Italy, Norway, Poland, Singapore, Spain, Sweden, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 4, 2008
Enrollment StartApr 1, 2008
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 18.1 years ago

Interventions

Pasireotidedrug

Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed

Octreotidedrug

Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed